Vanderbilt-Ingram Cancer Center SPORE in Gastrointestinal Cancer

$2,398,107P50FY2025CANIH

Vanderbilt University Medical Center, Nashville TN

Investigators

Linked publications & trials

Paper 39641198 Paper 39478207 Paper 39478141 Paper 39404772 Paper 39169060 Paper 39167600 Paper 39140467 Paper 39120954 Paper 39107918 Paper 38991830 Paper 38833684 Paper 38830977 Paper 38815928 Paper 38690771 Paper 38571435 Paper 38373106 Paper 38272100 Paper 38237908 Paper 38212428 Paper 38202281 Paper 38117502 Paper 38065082 Paper 37974020 Paper 37863104 Paper 37844197 Paper 37840781 Paper 37802423 Paper 37791878 Paper 37664174 Paper 37574015 Paper 37552655 Paper 37496679 Paper 37486582 Paper 37476546 Paper 37461634 Paper 37444556 Paper 37402366 Paper 37358310 Paper 37357017 Paper 37336886 Paper 37319387 Paper 37253090 Paper 37167978 Paper 37166989 Paper 37089816 Paper 36997301 Paper 36993731 Paper 36961012 Paper 36961000 Paper 36915679 Paper 36914899 Paper 36823545 Paper 36807140 Paper 36737375 Paper 36726342 Paper 36574664 Paper 36520636 Paper 36311879 Paper 36223499 Paper 36049656 Paper 36017308 Paper 35981544 Paper 35958027 Paper 35880121 Paper 35724732 Paper 35700772 Paper 35686747 Paper 35678528 Paper 35600339 Paper 35523142 Paper 35503250 Paper 35483629 Paper 35436124 Paper 35289315 Paper 35284114 Paper 35280777 Paper 35279145 Paper 35252869 Paper 35084791 Paper 35048125 Paper 34986344 Paper 34983062 Paper 34910928 Paper 34824477 Paper 34774792 Paper 34767785 Paper 34695382 Paper 34688039 Paper 34607083 Paper 34572448 Paper 34564899 Paper 34497145 Paper 34455107 Paper 34385401 Paper 34329783 Paper 34060626 Paper 34037774 Paper 33989815 Paper 33982010 Paper 33853321

Abstract

PROJECT SUMMARY/ABSTRACT: Overall This application is an A1 submission of the Vanderbilt-Ingram Cancer Center Gastrointestinal SPORE, which will focus on colorectal cancer, the second leading cause of cancer-related deaths in the United States. Our potential for success is high based on 1) productivity during the previous cycle of the GI SPORE, 2) exceedingly strong institutional support, 3) recruitment of talented investigators to the field of GI cancer through career enhancement and developmental research funding, 4) access to unparalleled resources for drug discovery and ex vivo models, 5) a blend of young and seasoned clinical investigators and basic scientists working together in a highly collegial environment, 6) a committed group of patient advocates now organized into a patient advocacy council and 7) multiple inter-SPORE, pharmaceutical, national and international horizontal and vertical collaborations. We narrowly missed being funded on our A0 submission and have been provided interim funding by NCI. We propose three projects and four supporting cores.

View original record on NIH RePORTER →